Why participate in a clinical trial?

Participating in a clinical trial can offer a range of benefits for you and others, while playing a crucial role in advancing medical knowledge and treatment options. If you or a loved one is looking to gain access to new and innovative treatments that are not yet available to the general public or have a condition that has limited or no effective treatment options, we invite you to look through the studies listed below that are available through our institution. 

Why should someone who is healthy participate in a study?

Some clinical trials allow for participation by healthy individuals. By participating in a clinical trial, healthy individuals also contribute to the advancement of medical science. Their involvement helps researchers determine the effectiveness and safety of new treatments, which can ultimately lead to better healthcare for everyone.

How do I find a clinical trial?

Click on a Category below to Search clinical trials by Subject or Location or you can put a word in the search box.

Clinical Trials are held in various locations around Shreveport-Bossier and in other cities. Information on the location and who to contact with questions is included in the information on each trial link below.

   

If the "SEARCH" is not working as expected, be sure that "ALL" is selected in the Categories below.

This protocol will direct the execution of subject enrollment and the sample collection for the VITROS Immunodiagnostic Products Free PSA III (VITROS Free PSA III) test. The purpose of this clinical study is to collect data to substantiate the use of the VITROS Free PSA III test as an aid in distinction of prostate cancer from benign prostatic conditions.

Read More about VITROS Free PSA III

Subjects presenting with symptomatic BPH seeking minimally invasive therapy will be approached to discuss study participation. Medical history will be reviewed, and initial assessments will be completed to assess suitability for treatment with the Optilume BPH Catheter System. Following treatment subjects will be assessed at 1 month, 3 months, 6 months, 1 year, and annually through 5 years post-treatment.

Read More about PEAK

The purpose of this study is to investigate the effects of oral administration of 1 mg/day V117957 each evening in female subjects with overactive bladder syndrome as compared to placebo. The study will consist of a Screening/Washout Period (up to 4 weeks), Single-blind Placebo Run-in Period (2 weeks), Double-blind Treatment Period (8 weeks), Single-blind Placebo Washout Period (1 week), and Follow-up Period (up to 1 week).

Read More about Study of V117957 in Overactive Bladder Syndrome

The goal of this prospective, multicenter, single-arm study is to test the safety and effectiveness of eCoin ® tibial nerve stimulation in subjects having overactive bladder (OAB) with urgency urinary incontinence (UUI). 

Read More about RECIPE

This is a Phase IIb, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and pharmacokinetics of astegolimab in combination with standard of care (SOC) compared with placebo in combination with SOC in patients with COPD who are former or current smokers and have a history of frequent exacerbations.

Read More about COPD GB43311

This study is looking to determine if Lumateperone improves motivation in patients with schizophrenia or schizoaffective disorders who show high levels of apathy as judged by AES-C-Apathy assessment and to examine a possible correlation between improvement in apathy scores and changes in elements of the PANSS (Positive and Negative Syndrome Scale) due to treatment with Lumateperone.

Read More about Apathy in Psychotic Disorders

The overall objective of this study is to evaluate the efficacy and safety of BIIB059 compared to placebo in participants with active SCLE and/or CCLE with or without systemic manifestations and refractory and/or intolerant to antimalarials. The objectives of the study are different for each portion of the study.

Read More about AMETHYST

This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group, large simple trial to investigate the efficacy and safety of a single intravenous (IV) infusion of BE1116 in subjects who have traumatic injury, with confirmed or suspected acute major bleeding and / or predicted to receive a large volume blood product transfusion.

Read More about TAP Study

This prospective, multi-center, randomized, controlled clinical trial is being conducted to evaluate the safety and efficacy of the pdSTIM System to facilitate weaning from mechanical ventilation through phrenic nerve stimulation.

Read More about ReInvigorate

A prospective, multicenter, single arm, interventional study. The target patient population for this study are adult subjects with WNBAs of the anterior and posterior intracranial circulation. The primary effectiveness outcome of the study is adequate intracranial aneurysm occlusion on the 1 year angiogram as adjudicated by a core laboratory.

Read More about WEB PAS

The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.

Read More about TILIA

This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis included candidemia. Subjects will receive intravenous echinocandin followed by oral Ibrexafungerp (SCY-078) vs intravenous echinocandin followed by oral fluconazole.

Read More about Mario SCY-078-302

A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized 1:1 to either fenebrutinib or teriflunomide. Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study.

Read More about FENhance

Patients randomized to the treatment arm will undergo a fluoroscopically and intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) guided trans-septal puncture and Corvia Atrial Shunt implant procedure.

Read More about Responder-HF

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.

Read More about VLX-601

The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called bivalent BNT162b2 Omicron containing vaccine) in healthy children. The trial is divided into 4 individual studies or substudies based on age group and prior history of COVID-19 vaccinations. All participants in each of the 4 sub-studies study vaccine as a shot depending on what group they are in.

  • Substudy A design: includes participants 6 months through less than 4 years 3 months of age who have not received a previous coronavirus vaccination (COVID-19 vaccine naïve) and will receive 3 doses of study vaccine as their initial which may be followed by a fourth dose of study vaccine.
  • Substudy B design: includes 6 months through less than 5 years of age who have either received 2 or 3 prior doses of BNT162b2 and will receive study vaccine as their third or fourth dose.
  • Substudy D design: includes participants 5 through less than12 years of age who have received 2 or 3 prior doses of BNT162b2 and will receive study vaccine as their third or fourth dose.
Read More about Pfizer C4591048

The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.

Read More about Rebirth

New IDEAS is an observational, open-label, longitudinal cohort study designed to address the requirements of the CED provisions of the NCD on beta-amyloid PET. Building on the initial Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) study, New IDEAS will evaluate the association between amyloid PET and patient-centered outcomes in an expanded and more ethnoracially and clinically diverse group of Medicare participants presenting with cognitive impairment.

Read More about New IDEAS

The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke or high risk TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.

Read More about SleepSmart

The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of obinutuzumab in adolescent participants (12 to < 18 years old) with International Society of Nephrology and the Renal Pathology Society (ISN/RPS) Class III or IV active lupus nephritis (proliferative LN) receiving standard of care therapy with mycophenolate mofetil (MMF) an

Read More about Posterity

The RejuvenAir® System is a cryosurgical device that applies medical-grade liquid nitrogen to the treatment area via a radial head catheter in a small, accurately directed spray. Cryotherapy with the RejuvenAir® System is designed to induce a regenerative endobronchial tissue effect by: 1) destroying via cryotherapy the abnormal surface epithelium that has become overgrown with mucin producing goblet cells, 2) thus allowing normal bronchial epithelium with a regrowth of ciliated epithelial cells that will facilitate the removal of mucins from the bronchial airways and 3) lead to a reduction in chronic inflammation and its accompanying mucosal swelling with resultant increase in the treated airway diameter. This reversal of inflamed epithelium may also lessen systemic inflammation.

Trial Details: 

Read More about SPRAY-CB RejuvenAir

The primary objective is to compare the safety and efficacy of the PMX cartridge (Toraymyxin) based on mortality at 28 days in patients with septic shock and endotoxemia who are treated with standard medical care plus the use of the PMX cartridge, versus patients who receive standard medical care alone.

Read More about TIGRIS Trial

To demonstrate safety and assess the clinical use and outcomes of the LUTONIXÒ DCB for treatment of dysfunctional AV fistulae located in the arm in a heterogeneous patient population in real world clinical practice.

Read More about Lutonix AV PAS

This prospective, randomized, controlled study evaluates the safety and efficacy of a preterm birth (PTB) prevention strategy versus standard of care pregnancy management to reduce the incidence of adverse pregnancy outcomes. Prospective subjects will be randomized to the PTB prevention strategy or to standard of care management (Control arm).  Subjects randomized to the preterm birth prevention strategy will receive either routine standard of care pregnancy management or a multimodal intervention protocol reserved for higher risk pregnancies based on the results of a commercially-available laboratory developed test, PreTRM® (Sera Prognostics, Inc).  The intervention protocol utilizes well-established high-risk pregnancy interventions to improve maternal and neonatal health outcomes. 

Read More about The PRIME Study

The primary objectives of the study are: • To evaluate the safety of IV peramivir (study drug) in infants from birth to 6 months of age infected with IAV or IBV • To evaluate the PK of a single IV dose of peramivir in infants from birth to 6 months of age infected with IAV or IBV

Read More about BioCryst 1812-307

The objective of this multicenter prospective study is to collect urine samples to validate the NEPHROCLEARTM CCL14 Test in intensive care unit (ICU) patients with moderate to severe (Stage 2 or 3) acute kidney injury (AKI) as an aid in the risk assessment for developing persistent severe AKI (Stage 3 AKI lasting >72 hours) within 48 hours of patient assessment. The study is observational and will have no impact on the medical management of the subject.

Read More about AST-132 Diamond

The objective of this study is to evaluate real world long-term functional outcomes, safety and performance of the Indigo Aspiration System for the treatment of pulmonary embolism (PE)

Read More about STRIKE-PE

The objective of this study is to demonstrate the safety and efficacy of the Indigo Aspiration system for percutaneous mechanical thrombectomy in a population presenting with obstruction due to deep vein thrombosis (DVT) who are eligible for treatment.

Read More about BOLT

The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study treatment works in the study) of the study medicine (called nirmatrelvir/ritonavir) for potential treatment of coronavirus disease 2019 (COVID-19). The study medicine will be given to patients under 18 years of age with COVID-19 that are not hospitalized but are at risk for severe disease.

Read More about Pfizer C4671026

The primary objective is to assess whether the initiation of spironolactone or eplerenone plus standard of care compared to standard of care alone reduces the incidence rate for total heart failure (HF) hospitalizations or cardiovascular (CV) death in HFpEF, studied with the pragmatic Registry-based Randomized Clinical Trial (RRCT) methodology.

Read More about SPIRRIT-HFpEF

The purpose of this study is to compare any good and bad effects of using aspirin after someone has completed the usual chemotherapy, surgery and/or radiation therapy for breast cancer. Some studies have suggested that aspirin may lower the risk of breast cancer coming back, but others have not, so we do not know if aspirin will help decrease breast cancer recurrence. This study will evaluate whether patients taking aspirin once per day will have a lower rate of cancer recurrence than patients taking a placebo. A placebo is a tablet that looks like the study drug (aspirin), but contains no medication.

Read More about Aspirin for Breast Cancer Study

The purpose of this study is to look at the effects of the chemotherapy drug, carboplatin, given with the usual chemotherapy drugs after surgery, compared to the usual chemotherapy drugs given without carboplatin.  The addition to the usual chemotherapy could prevent your cancer from returning, but it could also cause side effects.  This study will allow the researchers to know whether giving carboplatin with the usual chemotherapy is better, the same, or worse than giving the usual chemotherapy. 

Read More about Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Treatment of Breast Cancer

CONTACT CLINICAL TRIALS

Office Location
Monday - Friday ( 8:00am - 4:30pm)
LSU Health Shreveport
Admin Building 2nd Floor
1501 Kings Highway
Shreveport, LA 71103

Phone: (318) 675-8306
Email:  ctmt@lsuhs.edu

Text for Seal: %22Full AAHRPP Accreditation - Association for the Accreditation of Human Research Protection Programs, Inc.%22